http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11117565&dopt=Abstract
Serum alanine aminotransferase levels in relation to
hepatitis B and C virus infections among drug abusers in an area hyperendemic
for hepatitis B.
Chang CJ, Ko YC, Liu HW.
Department of Family Medicine, and School of Public Health, Kaohsiung Medical
College, Taiwan.
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the major
agents responsible for hepatitis in Taiwan. The purpose of this study was to
assess the serum alanine aminotransferase (ALT) activity in relation to HBV and
HCV infection among drug abusers. This survey included 769 male drug abusers
aged 14-59 years, from the Kaohsiung Narcotic Abstention Institute and Kaohsiung
Prision. The prevalence of HBsAg seropositivity was 21.5%, and anti-HCV
seropositivity was 27.2%, respectively. Drug abusers with HBsAg or anti-HCV had
higher serum AST and ALT levels than those without HBsAg and anti-HCV.
The prevalence of raised ALT and AST (>
or =45 IU/liter)
in the HCV-positive
group was more significant than in the negative group, while that of the
HBsAg-positive group did not reach statistical significance. Among the
HCV-positive
group, ALT levels are more closely associated with
HCV
infection than AST levels. Our results indicated that
HCV
infection plays an important role in the etiology of raised ALT activity among
drug abusers, while HBV infection plays a minor role. ALT screening still
remains a simple and valuable method in the early recognition of HCV infection.
PMID: 11117565 [PubMed - indexed for MEDLINE]
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.